1. Search Result
Search Result
Isoforms Recommended: EP
Results for "

EP

" in MedChemExpress (MCE) Product Catalog:

333

Inhibitors & Agonists

1

Screening Libraries

3

Biochemical Assay Reagents

12

Peptides

3

Inhibitory Antibodies

14

Natural
Products

28

Recombinant Proteins

27

Isotope-Labeled Compounds

16

Antibodies

15

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-152943
    MTK458
    4 Publications Verification

    EP-0035985

    PINK1/Parkin Mitophagy Mitochondrial Metabolism Neurological Disease Cancer
    MTK458 is an orally active brain penetrant PINK1 activator. MTK458 binds to PINK1 and stabilizes an active heterocomplex, thereby increasing mitophagy. MTK458 can be used for research on Parkinson's disease .
    MTK458
  • HY-14383
    Vosilasarm
    5+ Cited Publications

    RAD140; EP0062

    Androgen Receptor Neurological Disease Endocrinology Cancer
    Vosilasarm (RAD140) is a potent, orally active, nonsteroidal selective androgen receptor modulator (SARM) with a Ki of 7 nM. Vosilasarm shows good selectivity over other steroid hormone nuclear receptors .
    Vosilasarm
  • HY-14820A

    EP-1572 acetate; AEZS-130 acetate

    GHSR Neurological Disease Endocrinology Cancer
    Macimorelin (EP-1572) acetate, a GH secretagogue, is an orally active GHSR agonist. Macimorelin acetate stimulates GH release. Macimorelin acetate can be used in the research of adult growth hormone deficiency (AGHD), and Cancer anorexia-cachexia syndrome (CACS) .
    Macimorelin acetate
  • HY-136938
    NEO2734
    4 Publications Verification

    EP31670

    Epigenetic Reader Domain Histone Acetyltransferase Cancer
    NEO2734 (EP31670) is an orally active dual p300/CBP and BET bromodomain selective inhibitor, with IC50 values of <30 nM for both p300/CBP and BET bromodomains . NEO2734 is active in SPOP mutant and wild-type prostate cancer .
    NEO2734
  • HY-136645

    Prostaglandin Receptor Cancer
    EP4 receptor antagonist 2 (Compound 8) is a tricyclic spiro-based EP4 receptor antagonist with microsomal stability .
    EP4 receptor antagonist 2
  • HY-145794

    Liposome Cancer
    ZA3-Ep10 is a zwitterionic lipid used in lipid nanoparticles formulation for in vivo RNA delivery.
    ZA3-Ep10
  • HY-133123
    EP4 receptor antagonist 1
    2 Publications Verification

    Prostaglandin Receptor Inflammation/Immunology Cancer
    EP4 receptor antagonist 1 is a highly potent and selective competitive prostanoid EP4 receptor antagonist for cancer immunotherapy. EP4 receptor antagonist 1 inhibits human and mouse EP4 receptor with IC50s of 6.1 nM and 16.2 nM, respectively. IC50s >10 μM for human EP1, EP2,and EP3 receptors .
    EP4 receptor antagonist 1
  • HY-176293

    Prostaglandin Receptor Amyloid-β Neurological Disease
    EP2 receptor antagonist-3 is a selective EP2 receptor antagonist (IC50: 8 nM in hEP2 SPA assay, 50 nM in hEP2 cAMP assay). EP2 receptor antagonist-3 increases the macrophage-mediated clearance of Amyloid-β plaques. EP2 receptor antagonist-3 can be used for the study of alzheimer’s diseases .
    EP2 receptor antagonist-3
  • HY-156613

    EP-7041

    Factor XI Infection
    Frunexian (EP-7041) is a selective and potent inhibitor of coagulation factor XI/activated factor XI, targeting to factor XIa. Frunexian exhibits antithrombotic activity, with no bleeding liability in rat mesenteric arterial puncture model. Frunexian can be used in extracorporeal membrane oxygenation (ECMO) research .
    Frunexian
  • HY-101172

    EP-A-501322

    5-HT Receptor Cardiovascular Disease
    RS 23597-190 (EP-A-501322) is a high affinity and selective 5-HT4 receptor antagonist. RS 23597-190 inhibits Serotonin (HY-B1473A)-induced tachycardia. RS 23597-190 significantly inhibits superoxide production in high glucose .
    RS 23597-190
  • HY-153935

    Prostaglandin Receptor Inflammation/Immunology Cancer
    EP4-IN-1 is a potent prostanoid EP4 receptor inhibitor. EP4-IN-1 is extracted from patent WO2023025270 (example 1), and exhibits prospect in tumor immunity and anti-inflammatory analgesia research .
    EP4-IN-1
  • HY-168878

    METTL3 Cancer
    EP652 is a METTL3 inhibitor and antitumor agent with IC50 values of 2 nM, <10 nM, and 37 nM in SPA, intracellular, and ATPlite assays, respectively. EP652 exhibits high selectivity against 40 other methyltransferases and FTO, and possesses favorable pharmacokinetic parameters. EP652 reduces intracellular N 6-methyladenosine (m 6A) levels in mRNA. EP652 inhibits tumor growth and progression of both hematologic malignancies and solid tumors. EP652 can be used for the research of acute myeloid leukemia, ovarian cancer, non-small cell lung cancer, and hypopharyngeal squamous cell carcinoma .
    EP652
  • HY-153129

    Prostaglandin Receptor Endocrinology
    EP2 receptor antagonist-2 (CID891729) is an antagonist of EP2 receptor. EP2 receptor antagonist-2 inhibits the EP2 receptor activation induced by PGE2. EP2 receptor antagonist-2 also suppresses lactate dehydrogenase (LDH) release induced by N-methyl-D-aspartate (NMDA) .
    EP2 receptor antagonist-2
  • HY-145684

    Prostaglandin Receptor Inflammation/Immunology
    EP2 receptor antagonist-1 (compound 1) is a potent, reversible, and agonist dependent allosteric prostaglandin EP2 receptor antagonist. EP2 receptor antagonist-1 shows anti-inflammatory effects .
    EP2 receptor antagonist-1
  • HY-147226

    Prostaglandin Receptor Neurological Disease Endocrinology
    EP3 antagonist 3 (compound 2) is an orally active, potent and selective EP3 antagonist, with a pKi of 8.3. EP3 antagonist 3 shows excellent pharmacokinetic properties. EP3 antagonist 3 can be used for overactive bladder (OAB) research .
    EP3 antagonist 3
  • HY-118609

    Prostaglandin Receptor Inflammation/Immunology
    EP4 receptor agonist 2 (compound 31) a potent EP4 receptor agonist with an EC50 value of 0.8 nM; Ki values of >100000, 38000, 3.1 nM for EP2, EP3, EP4 respectively .
    EP4 receptor agonist 2
  • HY-RS04405

    Small Interfering RNA (siRNA) Others

    EP300 Human Pre-designed siRNA Set A contains three designed siRNAs for EP300 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    EP300 Human Pre-designed siRNA Set A
    EP300 Human Pre-designed siRNA Set A
  • HY-14820

    EP-1572; AEZS-130

    GHSR Endocrinology Cancer
    Macimorelin (EP-1572), a GH secretagogue, is an orally active GHSR agonist. Macimorelin stimulates GH release. Macimorelin can be used in the research of adult growth hormone deficiency (AGHD), and Cancer anorexia-cachexia syndrome (CACS) .
    Macimorelin
  • HY-169859

    Prostaglandin Receptor Interleukin Related Inflammation/Immunology Cancer
    EP4 receptor antagonist 7 (Compound 14) is an antagonist of the prostaglandin E2 (PGE2) receptor subtype EP4 with an IC50 value of 1.1 nM. EP4 receptor antagonist 7 inhibits PGE2-induced β-arrestin recruitment in HEK293 cells with an IC50 value of 0.9 nM. EP4 receptor antagonist 7 decreases PGE2-induced expression of mRNA encoding IL-4, macrophage mannose receptor 1 (Mrc1), chitinase-like protein 3 (Chil3), chemokine (C-X-C) motif ligand 1 (Cxcl1), triggering receptor expressed on myeloid cells 2 (Trem2), and arginase-1 (Arg1), in RAW 264.7 macrophages. EP4 receptor antagonist 7 combined with an anti-PD-1 antibody inhibits tumor growth and increases infiltration of CD 8+ T cells into tumors in a CT26 murine colon cancer model .
    EP4 receptor antagonist 7
  • HY-P4144

    Phor18-LHRH (338613); EP-100

    GnRH Receptor Endocrinology Cancer
    Onvitrelin ucalontide ([Phor18-LHRH (338613)]) is an analogue of luteinizing hormone releasing hormone (LHRH) with antineoplastic activity. Onvitrelin ucalontide is a peptide with sequences of KFAKFAKKFAKFAKKFAKQHWSYGLRPG. Onvitrelin ucalontide effectively inhibits breast cancer, ovarian cancer and prostate cancer xenografts in mouse model .
    Onvitrelin ucalontide
  • HY-P2696

    Transmembrane Glycoprotein Cardiovascular Disease
    EP 80317 is a selective CD36 ligand. EP 80317 protects the heart against damage and dysfunction elicited by myocardial ischaemia and reperfusion (MI/R), along with a transient reduction in peripheral lipolysis. EP 80317 can be used for the study of cardiovascular disease .
    EP 80317
  • HY-P5702

    Bacterial Apoptosis Fungal Infection
    EP3 is an antimicrobial peptide. EP3 has antibacterial and antifungal activities. EP3 inhibits E. gallinarum, P. pyocyanea, A. baumanii, K. terrigena with a MIC value of 12.85 μg/mL. EP3 also shows antitumor activity against cancer cells, and induces cell apoptosis .
    EP3
  • HY-160260

    Epigenetic Reader Domain Histone Acetyltransferase Cancer
    EP300/CBP-IN-1 (compound 172) is a potent EP300/CBP inhibitor with IC50s of 2.3 nM and 2.1 nM for CBP BRD and EP300 BRD, respectively. EP300/CBP-IN-1 has the inhibitory effect on the proliferation of prostate cancer CWR22RV1 cells .
    EP300/CBP-IN-1
  • HY-173003

    Mas-related G-protein-coupled Receptor (MRGPR) Inflammation/Immunology
    EP-3945 is a potent agonist of Mas-related G protein-coupled receptor (MRGPR), more effective than the MRGPRD small molecule agonist β-Alanine (HY-N0230). MRGPR plays a crucial role in inflammatory pruritus and pain sensation. Additionally, MRGPR binds to Gq (MRGPRX2, MRGPRX4, MRGPRX1 couple with Gq; MRGPRX2, MRGPRD couple with Gi), with EP-3945 measured EC50 for Gq being 211.6 nM .
    EP-3945
  • HY-128362

    Histone Acetyltransferase Cancer
    Ep300/CREBBP-IN-8 (Example 37) is a potent and orally active Ep300 and CREBBP inhibitor with IC50s of 0.014 and 0.018 μM, respectively. Ep300/CREBBP-IN-8 can be used for the research of cancer .
    Ep300/CREBBP-IN-8
  • HY-178465

    Prostaglandin Receptor Interleukin Related Neurological Disease Inflammation/Immunology
    EP4 receptor antagonist 8 is an orally active EP4 antagonist (human EP4 IC50 = 6.40 nM). EP4 receptor antagonist 8 significantly reduced paw and joint swelling, inflammatory cell infiltration, cartilage damage, pannus formation, and joint bone erosion in arthritis (AIA) mice in a dose-dependent manner. EP4 receptor antagonist 8 can be used for the study of inflammatory pain .
    EP4 receptor antagonist 8
  • HY-105173

    EP 24332

    GnRH Receptor Histamine Receptor Endocrinology Cancer
    Teverelix (EP 24332) is a GnRH antagonist. Teverelix binds competitively and reversibly to GnRH receptors, thereby suppressing the release of LH and FSH. Teverelix can be used in the research of prostatic hyperplasia, endometriosis, and prostate cancer .
    Teverelix
  • HY-10397

    F1013

    Caspase Metabolic Disease
    EP1013 (F1013) is a broad-spectrum caspase selective inhibitor, used in the research of type 1 diabetes .
    EP1013
  • HY-159843

    EP395

    RSV Inflammation/Immunology
    Glasmacinal is a non-antibacterial macrolide agent with anti-inflammatory activity .
    Glasmacinal
  • HY-19305

    GHR Inflammation/Immunology
    EP-51216 is a growth hormone agonist peptide. EP-51216 increases food intake. EP-51216 can be used in the research of eating disorders .
    EP-51216
  • HY-118220

    Thrombin Cardiovascular Disease
    EP 171 is a TP receptor agonist and human platelet activator. EP 171 can induce constriction of guinea pig trachea, and the constriction can be inhibited by the TP receptor antagonist EP 092. EP 171 binds to TP receptors on intact human platelets with an IC50 of 2.9 nM .
    EP 171
  • HY-P5703

    Bacterial Apoptosis Fungal Infection
    EP5-1 is an antimicrobial peptide. EP5-1 has antibacterial and antifungal activities. EP5-1 also shows antitumor activity against cancer cells, and induces cell apoptosis. EP5-1 has antiviral activity against pseudorabies virus (PRV) .
    EP5-1
  • HY-149513

    c-Myc Apoptosis Cancer
    EP12 is a c-Myc inhibitor. EP12 is a c-Myc G4 stabilizer. EP12 induces apoptosis and DNA damage in multiple myeloma cells. EP12 disrupts the nuclear translocation of P65/P50 by interfering with the NF-κB signaling pathway. EP12 inhibits multiple myeloma growth .
    EP12
  • HY-P5701

    Bacterial Fungal Infection
    EP2 is an antimicrobial peptide. EP2 has antibacterial and antifungal activities. EP2 inhibits E. gallinarum, P. pyocyanea, A. baumanii, K. terrigena with a MIC value of 11.4 μg/mL .
    EP2
  • HY-120495

    Lipoxygenase Cancer
    EP6 is a potent 5-Lipoxygenase (5-LO) inhibitor. EP6 inhibits the cell viability of tumor cells without mutagenic activity. EP6 can be used in research of cancer .
    EP6
  • HY-159101

    EGFR PD-1/PD-L1 Cancer
    EP26 is a potent and orally active EGFR and PD-L1 inhibitor with IC50 values of 48.6 nM, 1.77 µM, respectively. EP26 decreased the protein expression of p-EGFR. EP26 induces cell cycle arrest at G0/G1 phase. EP26 has the potential for the research of glioblastoma .
    EP26
  • HY-101695

    Prostaglandin Receptor Neurological Disease Endocrinology
    EP1-antagonist-1 (Compound 27) is an EP1 antagonist with a pKi (FLIPR) of 9.31 and a pIC50 (binding) of 9.88. EP1-antagonist-1 can be used for the study of PGE2-mediated pain .
    EP1-antagonist-1
  • HY-160261S

    Epigenetic Reader Domain Cancer
    EP300/CBP-IN-2 is a potent EP300/CBP inhibitor that has good activity in vivo. EP300/CBP-IN-2 can be used for the research of cancer .
    EP300/CBP-IN-2
  • HY-152943A

    (Rac)-EP-0035985

    Mitophagy Cancer
    (Rac)-MTK458 (compound 16) is an activator of mitophagy. EP-0035985 is the isomer of EP-0035985 .
    (Rac)-MTK458
  • HY-150536

    HIV HIV Protease Infection
    EP39 is a potent HIV-1 maturation inhibitor. EP39 interacts with the SP1 domain of Gag. EP39 decreases the dynamics of CA-SP1 junction, by binding to the QVT motif of the SP1 domain, and perturbs the natural coil-helix equilibrium on both sides of the SP1 domain by stabilizing the transient alpha helical structure. EP39 acts by arresting maturation of HIV-1 thereby blocking its infectivity .
    EP39
  • HY-128367

    Histone Acetyltransferase Cancer
    Ep300/CREBBP-IN-4 (Example 56) is a potent Ep300 and CREBBP inhibitor with IC50s of 0.024 and 0.064 μM, respectively. Ep300/CREBBP-IN-4 can be used for the research of cancer .
    Ep300/CREBBP-IN-4
  • HY-128364

    Histone Acetyltransferase Cancer
    Ep300/CREBBP-IN-3 (Example 61) is a potent Ep300 and CREBBP inhibitor with IC50s of 0.056 and 0.095 μM, respectively. Ep300/CREBBP-IN-3 can be used for the research of cancer .
    Ep300/CREBBP-IN-3
  • HY-128363

    Histone Acetyltransferase Cancer
    Ep300/CREBBP-IN-2 (Example 73) is a potent and orally active Ep300 and CREBBP inhibitor with IC50s of 0.052 and 0.148 μM, respectively. Ep300/CREBBP-IN-2 can be used for the research of cancer .
    Ep300/CREBBP-IN-2
  • HY-P3417

    Bacterial Infection
    Amp1EP9 is an antimicrobial peptide. Amp1EP9 is a powerful tool for developing potent and nontoxic antimicrobial agents. Amp1EP9 has the potential for the research of multidrug-resistant bacterial infections .
    Amp1EP9
  • HY-177544

    Prostaglandin Receptor Endocrinology
    EP1 receptor antagonist-1 (Compound Example 5a freebase) is an EP1 prostaglandin receptor antagonist. EP1 receptor antagonist-1 is promising for research of urinary system-related diseases .
    EP1 receptor antagonist-1
  • HY-157496

    Prostaglandin Receptor Others
    EP3 antagonist 7 (Compound II) is an EP3 receptor antagonist. EP3 antagonist 7 can be used in the study of itching, pain, dysuria or stress disorders .
    EP3 antagonist 7
  • HY-W153917

    Biochemical Assay Reagents
    Diatrizoic acid EP impurity A is an organic compound with potential effects on biological systems and specific pharmacological activities. Diatrizoic acid EP impurity A can be used as a contrast agent in imaging examinations to enhance the clarity of images such as X-rays and CT scans. Diatrizoic acid EP impurity A has also been studied for the separation and analysis of compounds.
    Diatrizoic acid EP impurity A
  • HY-131664

    Prostaglandin Receptor Others
    EP3 antagonist 2 (Compound Exp 1) is a potent and selective EP3 receptor antagonist. EP3 antagonist 2 has a strong binding affinity for the human EP3 receptor (Ki: 3.3 nM) and significant antagonistic activity (IC50: 30.8 nM, determined by cellular cAMP levels) .
    EP3 antagonist 2
  • HY-153256

    Prostaglandin Receptor Metabolic Disease
    EP3 antagonist 4 (Compound 28) is an EP3 antagonist, with a Ki value of 2 nM for hEP. EP3 antagonist 4 shows low in vivo clearance, high oral AUC, and good bioavailability in the rat full PK studies. EP3 antagonist 4 can be used for research of beta cell dysfunction in diabetes .
    EP3 antagonist 4
  • HY-157494

    Prostaglandin Receptor Others
    EP3 antagonist 5 (Compound 22) is an EP3 receptor antagonist with an IC50 value of 67 nM .
    EP3 antagonist 5

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: